MYOBLOC
ApprovedSmall molecule
MYOBLOC is one of 11 small molecule programs targeting Atrophy. It is currently in Approved.
1
Indications
3
Total Trials
0
Active Trials
10
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Atrophy
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Namenda
AbbVieApproved
Evrysdi
RocheApproved
Zoladex
TTerSera Therapeutics LLC
Approved
MYOBLOC
SSolstice Neurosciences
Approved
Glucophage
EMD SeronoPhase 1
Clenbuterol
UUniversity of Copenhagen
Phase 2
Estrasorb
Novo NordiskPreclinical
Leuprorelin
TakedaPreclinical
Promestriene
UUniversity of Sao Paulo General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 8, 2000
MYOBLOC
BLA BLA103846
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MYOBLOC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSolstice Neurosciences